GALAPAGOS NV (GLPG.AS) Stock Price, Quote, News and Overview
AMS:GLPG - Euronext Amsterdam - BE0003818359 - Common Stock - Currency: EUR
GLPG.AS Quote, Performance and Key Statistics
AMS:GLPG (8/4/2025, 5:29:51 PM)
28.67
+0.59 (+2.1%)
The current stock price of GLPG.AS is 28.67 EUR. In the past month the price increased by 14.8%. In the past year, price increased by 19.49%.
GLPG.AS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 18.13 | 297.46B | ||
| AMG.DE | AMGEN INC | 14.03 | 137.28B | ||
| GIS.DE | GILEAD SCIENCES INC | 14.44 | 122.00B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | N/A | 101.91B | ||
| 1REGN.MI | REGENERON PHARMACEUTICALS | 12.18 | 52.62B | ||
| ARGX.BR | ARGENX SE | 77.52 | 35.96B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 23.33B | ||
| 1BIIB.MI | BIOGEN INC | 8.2 | 16.66B | ||
| IDP.DE | BIOGEN INC | 7.78 | 16.01B | ||
| 0QF.DE | MODERNA INC | N/A | 9.26B | ||
| 1MRNA.MI | MODERNA INC | N/A | 9.13B | ||
| ABVX.PA | ABIVAX SA | N/A | 4.62B |
Related stock screener links
About GLPG.AS
Company Profile
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 704 full-time employees. The company went IPO on 2005-05-06. The firm is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. The company develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. The company discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The firm acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
Company Info
GALAPAGOS NV
Generaal De Wittelaan L11 A3
MALINES (MECHELEN) ANTWERPEN BE
Employees: 704
Phone: 3215342900
GALAPAGOS NV / GLPG.AS FAQ
What is the stock price of GALAPAGOS NV today?
The current stock price of GLPG.AS is 28.67 EUR. The price increased by 2.1% in the last trading session.
What is the ticker symbol for GALAPAGOS NV stock?
The exchange symbol of GALAPAGOS NV is GLPG and it is listed on the Euronext Amsterdam exchange.
On which exchange is GLPG.AS stock listed?
GLPG.AS stock is listed on the Euronext Amsterdam exchange.
What is the price forecast or stock price prediction for GALAPAGOS NV stock?
17 analysts have analysed GLPG.AS and the average price target is 30.18 EUR. This implies a price increase of 5.27% is expected in the next year compared to the current price of 28.67. Check the GALAPAGOS NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GALAPAGOS NV worth?
GALAPAGOS NV (GLPG.AS) has a market capitalization of 1.89B EUR. This makes GLPG.AS a Small Cap stock.
How many employees does GALAPAGOS NV have?
GALAPAGOS NV (GLPG.AS) currently has 704 employees.
What are the support and resistance levels for GALAPAGOS NV (GLPG.AS) stock?
GALAPAGOS NV (GLPG.AS) has a support level at 26.09 and a resistance level at 28.09. Check the full technical report for a detailed analysis of GLPG.AS support and resistance levels.
Is GALAPAGOS NV (GLPG.AS) expected to grow?
The Revenue of GALAPAGOS NV (GLPG.AS) is expected to decline by -7.45% in the next year. Check the estimates tab for more information on the GLPG.AS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy GALAPAGOS NV (GLPG.AS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GLPG.AS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GLPG.AS, evaluating the profitability, health, valuation and growth aspects
- GALAPAGOS NV (GLPG.AS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GALAPAGOS NV (GLPG.AS) Sales and EPS estimates to see what analysts future expectations are.
- GALAPAGOS NV (GLPG.AS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GALAPAGOS NV (GLPG.AS) Insider and Institutional Ownership to learn about the owners and their transactions.
- GALAPAGOS NV (GLPG.AS) Stock Chart to make your own analysis
- GALAPAGOS NV (GLPG.AS) Latest news and press-releases to stay up to date.
Does GALAPAGOS NV (GLPG.AS) stock pay dividends?
GLPG.AS does not pay a dividend.
When does GALAPAGOS NV (GLPG.AS) report earnings?
GALAPAGOS NV (GLPG.AS) will report earnings on 2025-10-22.
What is the Price/Earnings (PE) ratio of GALAPAGOS NV (GLPG.AS)?
GALAPAGOS NV (GLPG.AS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.32).
GLPG.AS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to GLPG.AS. When comparing the yearly performance of all stocks, GLPG.AS is one of the better performing stocks in the market, outperforming 82.43% of all stocks.
GLPG.AS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GLPG.AS. The financial health of GLPG.AS is average, but there are quite some concerns on its profitability.
GLPG.AS Financial Highlights
Over the last trailing twelve months GLPG.AS reported a non-GAAP Earnings per Share(EPS) of -4.32. The EPS decreased by -200.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.45% | ||
| ROE | -10.75% | ||
| Debt/Equity | 0 |
GLPG.AS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 51% to GLPG.AS. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of -198.38% and a revenue growth -7.45% for GLPG.AS